NCT00334789

Belinostat and Isotretinoin in Treating Patients With Solid Tumors That Are Metastatic or That Cannot Be Removed by Surgery

A Phase 1 Trial of PXD101 in Combination With 13-cis-Retinoic Acid in Advanced Solid Tumor Malignancies

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 51 (actual)
• Sponsor: National Cancer Institute (NCI) · NIH
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This phase I trial is studying the side effects and best dose of belinostat when given together with isotretinoin in treating patients with metastatic or unresectable solid tumors. Belinostat may stop the growth of tumor cells by blocking blood flow to the tumor and by blocking some of the enzymes needed for cell growth. Isotretinoin may cause solid tumor cells to look more like normal cells, and to grow and spread more slowly. Giving belinostat together with isotretinoin may be an effective treatment for metastatic or unresectable solid tumors.

Detailed description

PRIMARY OBJECTIVES: I. To assess the safety and feasibility of combining PXD101 (belinostat) with 13-cis-retinoic acid \[13-cRA\] (isotretinoin) in patients with advanced solid tumor malignancies. II. To define the maximum tolerated dose (MTD) of PXD101 when administered in combination with 13-cRA and to describe the toxicities at each dose studied. III. To evaluate the pharmacokinetics of PXD101 and 13-cRA when given in combination. SECONDARY OBJECTIVES: I. To demonstrate upregulation of retinoic acid receptor-beta (RARβ) and retinoic X-receptor (RXR) expression in tumor tissues after treatment with PXD101 and 13-cRA. II. To measure apoptosis in tumor biopsies after treatment. III. To assess the change in gene expression after exposure to PXD101 and 13-cRA. IV. To document any clinical activity of the combination of PXD101 and 13-cRA. OUTLINE: This is a multicenter, dose-escalation study of belinostat. Patients receive belinostat intravenously (IV) over 30 minutes on days 1-5 and isotretinoin orally (PO) once daily (QD) on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of PXD101 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity during the first course of therapy. Once the MTD is determined, an expanded cohort of 10 patients are enrolled and treated at the MTD. These patients also undergo blood collection periodically during treatment for pharmacokinetic studies. All patients undergo blood collection, buccal scrapings, and tumor biopsies periodically for biomarker, pharmacodynamic, gene expression, and laboratory studies. After completion of study treatment, patients are followed for \>= 8 weeks.

Conditions

• Adult Solid Neoplasm

Interventions

Type	Name	Description
DRUG	Belinostat	Given IV
DRUG	Isotretinoin	Given orally
OTHER	Pharmacological Study	Correlative studies

Timeline

• Start date: 2006-06-12
• Primary completion: 2018-03-29
• Completion: 2018-03-29
• First posted: 2006-06-08
• Last updated: 2018-04-03

Locations

5 sites across 1 country: United States